Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix, Genomic Solutions, Orchid BioSciences, Yokogawa Electric

Premium

Affymetrix received US Patent No. 6,495,320, “Even length proportional amplification of nucleic acids.” The patent covers a method for the even length proportional amplification of nucleic acids.

 

Genomic Solutions of Ann Arbor, Mich., was granted US Patent No. 6,496,309, “Automated, CCD-based DNA micro-array imaging system.”

The patent covers a system that may be used for the automated acquisition, compilation, and analysis of images of fluorescently labeled samples of different types, including fluorescently labeled gene chip arrays.

 

Orchid BioSciences of Princeton, NJ, has received US Patent No. 6,495,363, “In-line complete spectral fluorescent imaging of nucleic acid molecules.” The patent covers a hyperspectral imaging technology and methods for employing such an apparatus for multi-dye/base detection of a nucleic acid molecule coupled to a solid surface.

 

Yokogawa Electric of Tokyo has received US Patent No. 6,494,373, “Biochip reader.” The patent covers a biochip reader for examining image information with an optical detector, by emitting light beams onto a biochip with samples arranged in spots or linear arrays. This system requires no scanning, so it is possible to read image information from multiple samples at high speed. There is no need for laser light thus little risk of bleaching.

 

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.